Independent directory Public ClinicalTrials.gov records United States
Institution Directory

Clinical trials at Ohio State University Wexner Medical Center

Sites in Columbus, OH

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 6:10 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1591
Shown on this page
12
Current sort
Recently updated
Campus scope
Ohio State University Wexner Medical Center, Columbus, OH
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within Ohio State University Wexner Medical Center, Columbus, OH. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 685–696 of 1,591 matching trials with a site at Ohio State University Wexner Medical Center, Columbus, OH.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Conditions
Coronary Artery Disease
Interventions
Coronary artery bypass grafting (CABG), Percutaneous coronary intervention (PCI)
Procedure
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2039
U.S. locations
18
States / cities
Glendale, California • Atlanta, Georgia • Carmel, Indiana + 12 more
Recruiting No phase listed Observational

Cardiothoracic Critical Care as Subspecialty and Its Core Competencies

NCT06370338
Status at this site: Recruiting
Conditions
Consensus Development
Interventions
Delphi Questionnaire
Other
Lead sponsor
Ohio State University
Other
Eligibility
Not listed
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Columbus, Ohio
Active, not recruiting Phase 2 Interventional Results available

Testing the Addition of Nivolumab to Chemotherapy in Treatment of Soft Tissue Sarcoma

NCT04339738
Site status not listed — check the official record
Conditions
Skin Angiosarcoma, Skin Radiation-Related Angiosarcoma, Visceral Angiosarcoma
Interventions
Biospecimen Collection, Cabozantinib S-malate, Computed Tomography, FDG-Positron Emission Tomography, Magnetic Resonance Imaging, Nivolumab, Paclitaxel, Quality-of-Life Assessment, Questionnaire Administration
Procedure · Drug · Biological + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
170
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 120 more
Active, not recruiting Phase 1 Interventional Results available

Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cancer

NCT03939897
Site status not listed — check the official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic HER2-Negative Breast Carcinoma, Metastatic Hormone Receptor-Positive Breast Carcinoma, Recurrent Breast Carcinoma
Interventions
Abemaciclib, Biopsy Procedure, Biospecimen Collection, Copanlisib Hydrochloride, Diagnostic Imaging Testing, Echocardiography Test, Fulvestrant, Multigated Acquisition Scan
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
14
States / cities
Birmingham, Alabama • Costa Mesa, California • Orange, California + 8 more
Recruiting Phase 1 Interventional

A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors

NCT06561685
Status at this site: Recruiting
Conditions
Metastatic Solid Tumor, Advanced Solid Tumor, Non-small Cell Lung Cancer, SMARCA4-Deficient Tumor
Interventions
LY4050784, Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed, Paclitaxel, Nab paclitaxel
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
17
States / cities
Santa Monica, California • Aurora, Colorado • Denver, Colorado + 10 more
Active, not recruiting Not applicable Interventional

Clinical Trial for Surgery of the Ulnar Nerve (SUN) at the Elbow

NCT04254185
Site status not listed — check the official record
Conditions
Neuropathy Ulnar
Interventions
Simple decompression, Subcutaneous anterior transposition
Procedure
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
378 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
10
States / cities
Atlanta, Georgia • Louisville, Kentucky • Baltimore, Maryland + 6 more
Recruiting Phase 2 Interventional

Third Party Viral Specific T-cells (VSTs)

NCT02532452
Status at this site: Recruiting
Conditions
Viral Infection, Viral Reactivation, Infection in an Immunocompromised Host
Interventions
Viral Specific VST Infusion
Biological
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
2 Days and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2029
U.S. locations
4
States / cities
Akron, Ohio • Cincinnati, Ohio • Columbus, Ohio
Active, not recruiting No phase listed Observational

A Study to Understand the Utility of the Force Feedback Instruments in Robotic Procedures Using da Vinci 5 Robot

NCT06879912
Site status not listed — check the official record
Conditions
Hernia, Inguinal, Hernia, Ventral, Colorectal, Thoracic, Gynecologic, Partial Nephrectomy
Interventions
Not listed
Lead sponsor
Intuitive Surgical
Industry
Eligibility
22 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
6
States / cities
San Diego, California • Miami, Florida • Gainesville, Georgia + 3 more
Conditions
Pancreatic Neoplasm
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Endoscopic Ultrasound, Endoscopic Ultrasound-Guided Fine-Needle Aspiration, Magnetic Resonance Imaging, Quality-of-Life Assessment, Questionnaire Administration, Surgical Procedure
Procedure · Other
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
50 Years to 75 Years
Enrollment
770 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2034
U.S. locations
413
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 294 more
Conditions
Locally Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging, Multigated Acquisition Scan, Sotorasib, Trastuzumab Deruxtecan
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
9
States / cities
Sacramento, California • Tampa, Florida • Wesley Chapel, Florida + 4 more
Active, not recruiting Phase 3 Interventional

Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer

NCT04340141
Site status not listed — check the official record
Conditions
Pancreatic Adenosquamous Carcinoma, Resectable Pancreatic Adenocarcinoma, Stage I Pancreatic Cancer AJCC v8, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8
Interventions
Oxaliplatin, Irinotecan Hydrochloride, Leucovorin Calcium, Fluorouracil, Resection, Questionnaire Administration
Drug · Procedure · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
358 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
441
States / cities
Birmingham, Alabama • Fairhope, Alabama • Mobile, Alabama + 325 more
Conditions
Advanced Breast Carcinoma, Advanced Colon Carcinoma, Advanced Colorectal Carcinoma, Advanced Endometrial Carcinoma, Advanced Gastric Carcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Advanced Malignant Solid Neoplasm, Advanced Salivary Gland Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, HER2-Positive Breast Carcinoma, Malignant Hepatobiliary Neoplasm, Metastatic Breast Carcinoma, Metastatic Colon Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Endometrial Carcinoma, Metastatic Gastric Carcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Salivary Gland Carcinoma, Stage III Colon Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8, Stage III Major Salivary Gland Cancer AJCC v8, Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8, Stage IV Colon Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IV Major Salivary Gland Cancer AJCC v8, Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8, Unresectable Breast Carcinoma, Unresectable Colon Carcinoma, Unresectable Colorectal Carcinoma, Unresectable Endometrial Carcinoma, Unresectable Gastric Carcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma, Unresectable Malignant Solid Neoplasm, Unresectable Salivary Gland Carcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Ceralasertib, Computed Tomography, Echocardiography Test, Multigated Acquisition Scan, Positron Emission Tomography, Trastuzumab Deruxtecan
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
23
States / cities
Irvine, California • Los Angeles, California • Orange, California + 16 more

About this Ohio State University Wexner Medical Center institution page

What this page lists
ClinicalTrials.gov records that list Ohio State University Wexner Medical Center in Columbus, OH as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, browse by condition, or browse by U.S. city.